Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
17.36
+0.30 (1.76%)
Teva Pharmaceutical Industries is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of a wide range of generic and specialty medications
The company is committed to improving patient access to high-quality medicines and focuses on therapeutic areas such as central nervous system disorders, pain management, respiratory diseases, and more. With a robust portfolio that includes both branded and generic products, Teva leverages its extensive research capabilities to innovate and provide solutions that meet the evolving healthcare needs of patients and healthcare professionals around the world.
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?
Discover the latest trends with last week's worst-performing large-cap stocks, including Manhattan Associates' steep decline following reduced financial guidance and the broader impact of China's DeepSeek AI on sectors like semiconductors and AI-related industries.
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of 70 cents per share.
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025.
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.
